Anti-cancer targeting drugs appear to be a new and powerful "weapon" for cancer therapies. These
targeting drugs are directed against specific molecules that are over-expressed or where certain unique factors are
aberrantly expressed either in cancer cells or in diseased cell sites. Compared with traditional chemotherapeutic
drugs, these targeting drugs have the advantages of high specificity, efficacy and less side effects. Target therapy
is a breakthrough and revolutionary advance in the field of cancer therapy. Tumor angiogenesis plays a key role in
tumor growth and metastasis and the mutation of tyrosine kinases is also strongly associated with cancer
progression. Thus, in this review, we will discuss the advances in the development of targeting anti-cancer drugs
by narrowing it down to small molecule tyrosine kinase inhibitors, monoclonal antibodies against epidermal
growth factor receptors belonging to the ErbB family of receptor tyrosine kinases and angiogenic inhibitors. It will also address concerns
for drug resistance and adverse events.
Keywords: Angiogenesis, cancer, combination therapy, signaling pathway, target therapy, tyrosine kinase.
Rights & PermissionsPrintExport